BioCentury

8:00 AM GMT, Nov 16, 2009
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Strategy

Leftovers in Enzon's refrigerator

Now that activist shareholders have won their two-year battle to restructure Enzon Pharmaceuticals Inc., the question is what will happen to the development stage assets that remain.

Last week, the company announced it will sell its specialty pharma business to Sigma-Tau S.p.A. The deal includes Enzon's four marketed products: Oncaspar pegaspargase for acute lymphoblastic leukemia (ALL); Adagen enzyme replacement therapy for severe combined immunodeficiency disease (SCID); DepoCyt Ara-C

Read the full 678 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.